What a year 2022 turned out to be! It was a year of growth and expansion, with many exciting successes for Selexis as well as for our clients. From commercial product launches to new service agreements, the launch of a new facility, and being awarded as a Great Place to Work for the fifth year in a row, it has been an incredible year.
In October, we appointed our first Chief Business Officer, Dr. Abdeleziz Toumi. Abdel leads Global Business Development for KBI and Selexis, spearheading the long-term client growth strategy and the building of key strategic relationships. Additionally, Abdel is responsible for the Program Management Office (PMO) organization where he oversees client program delivery.
"Learn from yesterday, live for today, hope for tomorrow."
Commercial Product Launches
In February, Selexis and Generium JSC announced the commercial launch of a biosimilar to treat atopic asthma, a disease that affects 70–90% of children and about 50% of adults. The treatment is also an indication for chronic spontaneous urticaria (itchy rash) in patients with elevated immunoglobulin E (IgE). This launch marks the third SUREtechnology Platform™-generated biosimilar to reach the market under agreements between Generium and Selexis and marks the ninth biologic overall to leverage Selexis’ cell line development platform.
Shortly after this outstanding achievement, Selexis reached a new milestone in April when its tenth commercial product developed with the SUREtechnology Platform™ gained approval. We are very proud of our teams and the robust technology that led us to these incredible and exciting achievements. It is the best motivation to know that our daily work reaches patients to improve their lives by preventing, diagnosing, and curing the diseases that impact them.
New Service Agreements
Selexis has signed three major service agreements in 2022 with Hemogenyx, Inotrem, and NexImmune.
Selexis will leverage its SUREtechnology Platform™ to advance Hemogenyx’s humanized CDX bispecific antibody designed to treat acute myeloid leukemia (AML).
Selexis entered its second service agreement this year to develop the cell line for Inotrem’s antibody-based candidate to address chronic inflammations by targeting the TREM-1 (triggering receptor expressed on myeloid cells-1) pathway.
Selexis and NexImmune signed a service agreement to advance multiple immunotherapies targeting rare cancers and autoimmune diseases and to advance two HLAs that can be used to expand treatments to more patients. Selexis cell lines will be used to manufacture HLA IgG4 fusion proteins and T Cell co-stimulatory monoclonal antibodies that will be incorporated into NexImmune’s proprietary AIM injectable nanoparticle modality.
Integrated Biologics Manufacturing Facility
Together with KBI Biopharma, Selexis launched an expanded, fully integrated mammalian contract development and manufacturing services facility in Geneva, Switzerland. In a city with over 200 pharmaceutical, biotech, and medical device companies, this new facility is situated alongside world-renowned pharmaceutical and cutting-edge startup companies.
The ~94,000 square-foot facility builds upon an existing market foothold by combining best-in-class cell line development (CLD) and expert mammalian manufacturing in a single location. Co-located with Selexis SA, the expansion enables industry-leading delivery of client programs through increased quality, efficiency, and time savings with deep expertise across a diverse portfolio of molecule formats.
Together, KBI and Selexis have developed a seamless approach that optimizes the client experience.
"For today's scientists, crossing borders between countries and disciplines is instrumental to opening doors to new questions and new answers."
Conferences, Congresses, and In-Person Events
In 2022, we had the pleasure of attending 27 conferences and congresses around the world. We greatly enjoyed connecting with many of our clients, colleagues, and future clients and learning about the latest developments in emerging areas of science and technology. 2023 is shaping up to be even more exciting, and we are looking forward to seeing many of you in the coming year.
Research, Publications, and Resources
Our scientific experts were busy in 2022, communicating their latest research and findings in various publications, tech talks, poster presentations, and webinars throughout the year.
- Webinar: SUREtechnology Platform™ to Overcome Phenotypic and Genetic Changes in CHO Cells
- Webinar: Exploring the limits of conventional small scale CHO fed batch for accelerated on-demand monoclonal antibody production
- Webinar: Streamlined Development for Efficient Production of Bispecific Molecules Using an Integrated Platform Process
- Whitepaper: Delivering on the Promise of Bispecifics: State-of-the-Art Bispecific Antibody Development
- Article in BioProcess International: Twenty Years of Innovation
"The more we know, the more we realize there is to know."
Stay tuned as additional tech talks, articles, and poster presentations become available. You can subscribe to our newsletter, Cell Lines, to stay up to date on all the latest news and developments that are on their way – together, we’ll make this next year the best one yet!